Our Research Areas
The Change Initiative brings together the rigour of health economics with the reach of a cross-sector coalition to address the challenges that matter most to global health systems.
Our research programmes are not academic exercises, they are designed from the outset to inform live policy debates, equip decision-makers with better evidence, and drive meaningful change in how health systems are organised, financed, and governed.
Each programme is developed collaboratively, with funding partners helping to shape the research agenda and an independent Expert Council ensuring the quality and credibility of everything we produce. Outputs range from flagship white papers and policy briefings to expert roundtables and public forums, all designed to translate evidence into action.
Our current programmes focus on two of the most consequential challenges facing global health policy today: the seismic shift in pharmaceutical pricing and access triggered by US policy reform, and the persistent failure of health systems worldwide to invest adequately in prevention.
Addressing Systemic Challenges in Financing Prevention
Prevention is one of the best investments a health system can make. The evidence for this is overwhelming. Yet across the world, healthcare spending remains heavily weighted toward acute and reactive care, while the interventions most likely to keep people healthy, and reduce long-term costs, remain chronically underfunded.
The Financing Prevention programme sets out to understand why, and to do something about it. Rather than revisiting the case for prevention, we take that as given and focus on the harder question: how do you actually fund it? Working with partners across sectors, we are examining alternative financing and contracting models, from outcomes-based payment to cross-sector investment vehicles and developing practical, actionable recommendations for governments, health systems, and private partners.
The goal is not another report that sits on a shelf. It is a set of tools that decision-makers can use.
From Washington to the World: US Policy Horizon Series
The global pharmaceutical landscape is changing faster than policy can keep up. Landmark reforms in the United States, including the Inflation Reduction Act and the proposed Most Favored Nation pricing policy, are reshaping the economics of drug development, pricing, and access not just domestically, but in every market that looks to the US as a reference point.
The US Policy Horizon Series examines these shifts from a global perspective. Through a multi-part programme of independent research and policy engagement, we are unpacking the implications for launch sequencing, value assessment, and market access across Europe, Asia, and beyond and exploring what a sustainable, globally equitable approach to pharmaceutical pricing might look like.
This is a fast-moving policy environment. Our aim is to provide the evidence and analysis that allows industry and policymakers to respond with confidence rather than react with uncertainty.